Brief: FDA Approves First Treatment For Cerebrotendinous Xanthomatosis, A Rare Lipid Storage Disease
21/02/2025 16:50
Feb 21 (Reuters) - FDA:
* FDA APPROVES FIRST TREATMENT FOR CEREBROTENDINOUS
XANTHOMATOSIS,
A RARE LIPID STORAGE DISEASE
Further company coverage: MIRM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirum Pharmaceuticals
See all newsMirum Pharmaceuticals Q3 net product sales surge, outlook raised
Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
Mirum climbs on positive late-stage trial results for liver disease drug
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX